Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
2,165
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

Jorge D. Oldana Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Benjamin C. Gigliob Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Eric Smitha Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Weiling Zhaob Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Deeanna M. Bouchardc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USAView further author information
,
Marija Ivanovica Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Yueh Z. Leea Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Frances A. Collichioc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;d Departments of Medicine, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Michael O. Meyersc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;i Departmant of Surgery, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Diana E. Wallackc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USAView further author information
,
Amber Abernethy-Leinwandb Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
Patricia K. Longc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;i Departmant of Surgery, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Dimitri G. Trembathe Departments of Pathology And Laboratory Medicine, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Paul B. Googef Departments of Dermatology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Madeline H. Kowalskig Department of Biostatistics, The University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USAView further author information
,
Anastasia Ivanovag Department of Biostatistics, The University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USAView further author information
,
Jennifer A. Ezzellh Departments of Cell Biology and Physiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Nana Nikolaishvili-Feinbergc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USAView further author information
,
Nancy E. Thomasc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;f Departments of Dermatology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Terence Z. Wonga Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
,
David W. Ollilac Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;i Departmant of Surgery, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USAView further author information
,
Zibo Lia Departments of Radiology, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USA;b Biomedical Research Imaging Center, UNC-CH,Chapel Hill, NC, USAView further author information
&
Stergios J. Moschosc Lineberger Comprehensive Cancer Center, UNC-CH, Chapel Hill, NC, USA;d Departments of Medicine, The University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8943-0845View further author information
ORCID Icon show all
Article: 2204753 | Received 07 Dec 2022, Accepted 16 Apr 2023, Published online: 26 Apr 2023

References

  • Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307–12. doi:10.1038/nrc3246. PMID: 22378190.
  • Singer K, Cheng W-C, Kreutz M, Ho P-C, Siska PJ. Immunometabolism in cancer at a glance. Dis Model Mech. 2018;11(8). dmm034272. doi:10.1242/dmm.034272.
  • Kedia-Mehta N, Finlay DK. Competition for nutrients and its role in controlling immune responses. Nat Commun. 2019;10(1):2123. doi:10.1038/s41467-019-10015-4.
  • Wang A, Luan HH, Medzhitov R. An evolutionary perspective on immunometabolism. Science. 2019;363(6423):eaar3932. doi:10.1126/science.aar3932.
  • Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–1080. [Epub 2012 Jan 19]. http://doi.org/10.1158/0008-5472.CAN-11-3218.
  • Perez-Castro L, Garcia R, Venkateswaran N, Barnes S, Conacci-Sorrell M. Tryptophan and its metabolites in normal physiology and cancer etiology. FEBS J. 2023;290(1):7–27. [Epub 2021 Nov 7]. doi:10.1111/febs.16245.
  • Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):eaaf9794. doi:10.1126/science.aaf9794.
  • Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–1274. [Epub 2003 Sep 21]. doi:10.1038/nm934.
  • Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223–3230. [Epub 2018 Sep 28]. doi:10.1200/JCO.2018.78.9602.
  • Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–1097. [Epub 2019 Jun 17]. doi:10.1016/S1470-2045(19)30274-8.
  • Sarrouilhe D, Mesnil M. Serotonin and human cancer: a critical view. Biochimie. 2019;161:46–50. [Epub 2018 Jun 21]. doi:10.1016/j.biochi.2018.06.016.
  • Nowak EC, de Vries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, Ha DG, Noelle RJ. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med. 2012;209(11):2127–3235. doi:10.1084/jem.20120408.
  • Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Wortsman J. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002;511(1–3):102–106. doi:10.1016/s0014-5793(01)03319-1.
  • Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, et al. IL2 Inducible T-cell kinase, a novel therapeutic target in melanoma. Clin Cancer Res. 2015;21(9):2167–2176. doi:10.1158/1078-0432.CCR-14-1826.
  • Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmeckel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012;7(1):42. doi:10.1186/1746-1596-7-42.
  • Googe PB, Theocharis S, Pergaris A, Li H, Yan Y, McKenna EF Jr, Moschos SJ. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial). Curr Probl Cancer. 2022;46(3):100862. [Epub 2022 Apr 2]. doi:10.1016/j.currproblcancer.2022.100862.
  • Juhasz C, Nahleh Z, Zitron I, Chugani DC, Janabi MZ, Bandyopadhyay S, Ali-Fehmi R, Mangner TJ, Chakraborty PK, Mittal S, et al. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol. 2012;39(7):926–932. [Epub 2012 Mar 22]. doi:10.1016/j.nucmedbio.2012.01.010.
  • Batista CE, Juhasz C, Muzik O, Kupsky WJ, Barger G, Chugani HT, Mittal S, Sood S, Chakraborty PK, Chugani DC. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol. 2009;11(6):460–466. [Epub May 12]. doi:10.1007/s11307-009-0225-0.
  • Moschos SJ, Eroglu Z, NI NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, et al. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021;31(2):162–172. doi:10.1097/CMR.0000000000000726.
  • Trembath DG, Davis ES, Rao S, Bradler E, Saada AF, Midkiff BR, Snavely AC, Ewend MG, Collichio FA, Lee CB, et al. Brain tumor microenvironment and angiogenesis in melanoma brain metastases. Front Oncol. 2020;10:604213. eCollection 2020. doi:10.3389/fonc.2020.604213.
  • Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50(3):340–347. doi:10.2967/jnumed.108.058461.
  • Zhao K, Wang C, Shi F, Huang Y, Ma L, Li M, Song Y. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. BMC Cancer. 2021;21(1):66. doi:10.1186/s12885-021-07784-x.
  • Badawy AAB. Targeting tryptophan availability to tumors: the answer to immune escape? Immunol Cell Biol. 2018;96(10):1026–1034. [Epub 2018 Jun 10]. doi:10.1111/imcb.12168.
  • Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363–1372. doi:10.1084/jem.189.9.1363.
  • Schneider MA, Heeb L, Beffinger MM, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethum U, Kobold S, Graf R, et al. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med. 2021;13(611):eabc8188. doi:10.1126/scitranslmed.abc8188.
  • van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015;6:34. eCollection 2015. doi:10.3389/fimmu.2015.00034.
  • Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity. 2022;55(1):14–30. doi:10.1016/j.immuni.2021.12.012.
  • Ho J, de Moura MB, Lin Y, Bateman NW, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012;11(1):76. doi:10.1186/1476-4598-11-76.
  • Bayci AWL, Baker DA, Somerset AE, Turkoglu O, Hothem Z, Callahan RE, Mandal R, Han B, Bjorndahl T, Wishart D, et al. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics. 2018;14(18):105. doi:10.1007/s11306-018-1398-9.
  • Horai T, Nishihara H, Hattori S, Tateishi R. Malignant melanoma producing serotonin. Cancer. 1979;43(1):294–298. doi:10.1002/1097-0142(197901)43:1<294:aid-cncr2820430142>3.0.co;2-v.
  • Kulke MH, Horsch D, Caplin ME, Anthony LB, Bergsland E, Oberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23. [Epub 2016 Oct 28]. doi:10.1200/JCO.2016.69.2780.
  • Giglio BC, Fei H, Wang M, Wang H, He L, Feng H, Wu Z, Lu H, Li Z. Synthesis of 5-[(18)F]Fluoro-alpha-methyl tryptophan: new trp based PET agents. Theranostics. 2017;7(6):1524–1530. eCollection 2017. doi:10.7150/thno.19371.
  • Wu X, Ma X, Zhong Y, Chen W, Xu M, Zhang H, Wang L, Tu X, Han Z, Zhao W, et al. Development of [18F]F-5-OMe-tryptophans through photoredox radiofluorination: a new method to access tryptophan-based PET agents. J Med Chem. 2023 Feb 24;66(5):3262–3272. Online ahead of print. doi:10.1021/acs.jmedchem.2c01544.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.